Press Release: Fundraiser of the Year 2023
11 April 2024 We are thrilled to announce that we have two winners of our 2023 Fundraiser of the Year Award: Antony Rose and Michelle Gillies! These two incredible supporters went ‘above and beyond’ to support our vital research by spending 2023 raising funds and…
Press Release: Phase 2 clinical trial of Type 2 diabetes drug for treatment of Parkinson’s shows positive and promising results
3 April 2024 Results from a one-year, phase 2 clinical trial of the Type 2 diabetes drug lixisenatide suggest that the treatment may slow the progression of motor symptoms in Parkinson’s disease. The study is published on 4 April in The New England Journal of…
Press Release: Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed
23 February 2024 Cure Parkinson’s, in partnership with Van Andel Institute, is delighted to announce funding for a Phase 2 clinical of dapansutrile, an anti-inflammatory drug, to determine whether it can slow the progression of Parkinson’s. The DAPA-PD trial will evaluate the safety and tolerability…
Press Release: Cure Parkinson’s welcomes Rory Cellan-Jones as new patron
7 February 2024 Cure Parkinson’s is delighted to announce that Rory Cellan-Jones, former technology correspondent for the BBC, writer, ‘Movers & Shakers’ podcaster, technology advisor and owner of one the UK’s most beloved rescue dogs, has joined Cure Parkinson’s as a patron. Rory was diagnosed…
Cure Parkinson’s Director of Clinical Development, Dr Richard Wyse, named onHis Majesty The King’s New Year’s Honours List
2 January 2024 Cure Parkinson’s Director of Clinical Development, Dr Richard Wyse, has been selected for His Majesty The King’s New Year’s Honours List, for services to medicine in Parkinson’s disease. Dr Wyse has built an innovative, game-changing programme of research for Parkinson’s; he has…